Compare PMN & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMN | PPCB |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | Canada | Australia |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 20.4M |
| IPO Year | N/A | N/A |
| Metric | PMN | PPCB |
|---|---|---|
| Price | $7.23 | $0.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $72.67 | N/A |
| AVG Volume (30 Days) | 31.5K | ★ 268.9K |
| Earning Date | 11-12-2025 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.27 | $0.58 |
| 52 Week High | $39.75 | $145.46 |
| Indicator | PMN | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 58.74 | N/A |
| Support Level | $8.00 | N/A |
| Resistance Level | $8.73 | N/A |
| Average True Range (ATR) | 0.56 | 0.00 |
| MACD | -0.39 | 0.00 |
| Stochastic Oscillator | 9.86 | 0.00 |
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.